PLYMOUTH MEETING, Pa., June 30 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced the election of Paul K. Wotton, Ph.D., to Genaera's Board of Directors, bringing the membership total to seven. Dr. Wotton is expected to serve for the remainder of the Board's existing term through the Company's 2009 Annual Meeting.
"We are extremely pleased to add Paul Wotton to our Board of Directors. He has a proven record of success in business development, commercializing new business opportunities, and closing negotiations," said Jack Armstrong, president and CEO of Genaera. "I believe Paul's areas of expertise will be invaluable to Genaera. The management team and I look forward to working closely with Paul and the rest of our Board members to further develop strategic relationships."
Wotton previously served as CEO of Topigen Pharmaceuticals Inc., where he successfully completed multiple financial transactions that enabled the company to advance two preclinical programs to Phase 2 clinical trials. Prior to joining Topigen, Dr. Wotton was global head of business development at SkyePharma PLC, where he managed the business development and marketing function as well as implemented the largest drug delivery transaction at that time. Dr. Wotton has also served in senior-level positions at Eurand International BV, PENWEST Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme. He also currently serves on the board of Antares Pharma and is past chairman of the Emerging Companies Advisory Board of BIOTECanada.
"I am very pleased to join Genaera's Board. I believe Genaera has the
opportunity to develop MSI-1436 as a novel therapy with the potential to
treat both type 2 diabetes and obesity," states Paul
|SOURCE Genaera Corporation|
Copyright©2008 PR Newswire.
All rights reserved